Strand presents SignalPath LNPs as a way to direct mRNA payloads beyond the liver, including toward tumors and immune cells. It describes SignalLock RNA as a control layer that can deactivate expression in off-target tissues.
The company's SignalScript RNA program covers self-replicating and circular RNA designed for potency and durability. These capabilities are Strand's stated technology rationale for combining delivery, selectivity, and payload performance.
Strand's stated focus is genetic medicine for cancer and autoimmune disease, with delivery systems intended to reach tissues beyond the liver. Its website describes programs for solid tumors and future systemic delivery.
The company frames its technology around targeting, safety, and potency challenges in mRNA medicine. Its published materials show a clinical-stage pipeline and planned development of additional delivery and RNA approaches.
Strand Therapeutics develops programmable mRNA therapies and delivery technologies. The official site describes a clinical-stage pipeline for cancer and autoimmune indications, with separate approaches for targeting tissue, controlling expression, and extending RNA activity.
The company's articles page carries its press releases and publications, including announcements distributed through Business Wire. Strand's materials identify STX-001 and STX-003 among programs discussed on its pipeline pages.
